Drug Trial Radar · NCT07564401
A Study to Evaluate DJI136, a DLL3-targeted CAR-T Therapy
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
80
Planned (sponsor's estimate)
Start
Jun 16, 2026
Primary completion
Mar 3, 2031
Study completion Mar 3, 2031
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- May 4, 2026
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary efficacy of DJI136.
Conditions
- Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Interventions
DJI136Drug
DLL3 targeted CAR-T therapy administered by intravenous (i.v.) infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- All study parts: Incidence and severity of adverse events (AEs) and serious adverse events (SAEs)Time frame: Up to approximately 2 years
- All study parts: Incidence and severity of dose-limiting toxicities (DLTs)Time frame: 28 days
- Phase II Group A: Overall response rate (ORR) as per RECIST v1.1Time frame: Up to approximately 2 years
Locations
7 sites in 4 countries. Site status is shown where the registry gives one.
University of Kentucky
Lexington, Kentucky · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Fred Hutchinson Cancer Center
Seattle, Washington · Recruiting
Novartis Investigative Site
Clayton, Victoria, Australia · Recruiting
Novartis Investigative Site
Singapore, Singapore · Recruiting
Novartis Investigative Site
Seoul, South Korea · Recruiting
Novartis Investigative Site
Seoul, Seoul, South Korea · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.